Navigation Links
DNA Predicts Reaction to Drug That Fights Alcohol Dependence
Date:2/7/2008

MUSC researcher heads study, finds patients with gene variant drink less

CHARLESTON, S.C., Feb. 7 /PRNewswire/ -- Inherited genetic makeup often plays a role in determining the risk level for certain diseases, including alcoholism. Now new evidence-based research also shows a correlation between genotyping and the treatment of alcohol dependence.

Investigators participating in the National Institute on Alcohol Abuse and Alcoholism's 2001-2004 Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence Study (COMBINE Study) have discovered a direct correlation between patients with the Asp40 allele, a variation of the receptor gene OPRM1, and the drug naltrexone. Patients with this variant gene responded positively to the drug that blocks opiate receptors in the brain thereby reducing gratification from alcohol. Not only did patients who were treated with naltrexone and have the Asp40 gene variant go without harmful drinking for a longer period of time, but they also consumed fewer beverages on the days they did drink.

"For the first time we might have a 'personalized medical treatment' for alcoholism," said Raymond Anton, M.D., COMBINE Study principal investigator and director of the Center for Drug and Alcohol Programs at the Medical University of South Carolina (MUSC). "Discovery that a common genetic trait predicts treatment response to a commonly used medication should enhance its effectiveness and helps focus alcohol treatment in a cost-effective manner."

These findings provide a viable solution for the 15 to 25 percent of the population that carry the Asp40 allele. Alcohol counseling did not have the same affect as the drug, therefore researchers conclude genotyping is most beneficial without the therapy.

Gene variant carriers of all ethnicities who took naltrexone were more likely than their counterparts to have a good clinical result. However, since the study had more Caucasian participants, the results for this group are the most reliable.

About MUSC

Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 10,000 employees, including 1,300 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $1.3 billion. MUSC operates a 600-bed medical center, which includes a nationally recognized Children's Hospital and a leading Institute of Psychiatry. For more information on academic information or clinical services, visit http://www.musc.edu or http://www.muschealth.com.


'/>"/>
SOURCE Medical University of South Carolina
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Multigene Test Predicts Who Could Avoid Chemotherapy Despite Positive Lymph Nodes in Early Breast Cancer
2. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). ... Institute. The event is free and open to the public, but registration is ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):